期刊
BIOMATERIALS
卷 280, 期 -, 页码 -出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.biomaterials.2021.121297
关键词
Cancer vaccine; Local controlled release; Biomaterials; Oncoimmunotherapy; In situ delivery
资金
- Center for Immunotherapeutic Transport Oncophysics [U54CA210181]
- Houston Methodist Research Institute, through the Department of Defense [W81XWH-20-1-0600]
- Nancy Owens Breast Cancer Foundation
- Golfers Against Cancer
- Texas A&M University MD/PhD Program
- Houston Methodist Research Institute
- National Institutes of Health [R01AI097372]
- W. Bryan Trammell, Jr. Family Presidential Distinguished Chair in Allergy Immunology
Landmark successes in oncoimmunology have led to the development of cancer vaccines using biomaterials to enhance the host immune system against tumors. This review focuses on strategies to attract dendritic cells, activate them against tumor-specific antigens, and stimulate T cells in secondary lymphoid organs. Personalized cancer vaccines have the potential to generate long-term systemic immunity against patient- and tumor-specific antigens.
Landmark successes in oncoimmunology have led to development of therapeutics boosting the host immune system to eradicate local and distant tumors with impactful tumor reduction in a subset of patients. However, current immunotherapy modalities often demonstrate limited success when involving immunologically cold tumors and solid tumors. Here, we describe the role of various biomaterials to formulate cancer vaccines as a form of cancer immunotherapy, seeking to utilize the host immune system to activate and expand tumor-specific T cells. Biomaterial-based cancer vaccines enhance the cancer-immunity cycle by harnessing cellular recruitment and activation against tumor-specific antigens. In this review, we discuss biomaterial-based vaccine strategies to induce lymphocytic responses necessary to mediate anti-tumor immunity. We focus on strategies that selectively attract dendritic cells via immunostimulatory gradients, activate them against presented tumor-specific antigens, and induce effective cross-presentation to T cells in secondary lymphoid organs, thereby generating immunity. We posit that personalized cancer vaccines are promising targets to generate long-term systemic immunity against patient-and tumor-specific antigens to ensure long-term cancer remission.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据